Trade name: Synagis®
Generic names: palivizumab injection
Indication and Usage: Recommended monthly for premature born children during RSV season.
Ingredients: Palivizumab is a humanized monoclonal antibody (IgG1к) produced by recombinant DNA technology composite of human (95%) and murine (mice) (5%) antibody sequences. Chloride, glycine, and histidine are also included.
Manufacturer-listed adverse reactions | Synagis can cause: Anaphylaxis and anaphylactic shock, including fatal cases, Urticaria (Hives), Pruritus (Chronic itchy skin), Angioedema (Swelling), Dyspnea (Shortness of breath), Respiratory failure, Cyanosis (blue/purple skin), Hypotonia (Floppy infant syndrome), Hypotension (Low blood pressure), Unresponsiveness, Severe thrombocytopenia (platelet count less than 50,000 per microliter), Injection site reactions
Need more info? Click the link below for a helpful infographic you can view + save on your device.
